[1]吴金丽.阿立哌唑的临床应用[J].医学信息,2018,31(14):42-45.[doi:10.3969/j.issn.1006-1959.2018.14.014]
　WU Jin-li.Clinical Application of Aripiprazole[J].Journal of Medical Information,2018,31(14):42-45.[doi:10.3969/j.issn.1006-1959.2018.14.014]
点击复制

阿立哌唑的临床应用()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
31卷
期数:
2018年14期
页码:
42-45
栏目:
综述
出版日期:
2018-07-15

文章信息/Info

Title:
Clinical Application of Aripiprazole
文章编号:
1006-1959（2018）14-0042-04
作者:
吴金丽
天津市安宁医院临床一科，天津 300300
Author(s):
WU Jin-li
Department of Clinical Medicine,Subject One,Tianjin Anning Hospital,Tianjin 300300,China
关键词:
阿立哌唑; 精神分裂症; 抑郁症; 强迫症; 老年痴呆; 儿童抽动障碍
Keywords:
Key words：Aripiprazole; Schizophrenia; Depression; Obsessive-compulsive disorder; Senile dementia; Childhood tic disorder
分类号:
R971
DOI:
10.3969/j.issn.1006-1959.2018.14.014
文献标志码:
B
摘要:
非典型抗精神病药物阿立哌唑在精神科中的应用日趋广泛，不仅应用于精神分裂症的治疗，还作为心境稳定剂治疗情感障碍，而且应用于强迫症、躯体形式障碍、老年痴呆等的治疗，在青少年及儿童精神疾病如儿童抽动症、儿童精神分裂症的治疗中亦能取得一定的疗效，而且安全性良好，在女性精神分裂症患者中应用可以减少闭经的发生率。总之，阿立哌唑在精神科的临床使用日趋广泛，且发挥了较好的作用，本文对阿立哌唑的临床应用作一综述，为临床用药提供参考。
Abstract:
Abstract：The atypical antipsychotic drug aripiprazole is widely used in psychiatry,not only for the treatment of schizophrenia,but also as a mood stabilizer for the treatment of affective disorders,and for obsessive-compulsive disorder,somatoform disorders,senile dementia,etc.treatment,it can also achieve certain curative effects in the treatment of adolescents and children with mental disorders such as children's tic disorder and childhood schizophrenia,and it is safe.It can reduce the incidence of amenorrhea in women with schizophrenia.In conclusion,the clinical use of aripiprazole in psychiatry has become more and more extensive,and has played a good role.This article reviews the clinical application of aripiprazole and provides a reference for clinical use.

参考文献/References:

[1]段桂花,陈福新.阿立哌唑的临床应用研究进展[J].中国药物评价,2013,30(1):24-26. [2]于晶,顾广中.草酸艾司西酞普兰联合阿立哌唑治疗伴有精神病性症状的重度抑郁发作的临床分析[J].中国现代药物应用,2016,10(23):102-104. [3]张俊峰,游非,杨艳军.阿立哌唑与利培酮治疗精神分裂效果对比评定及观察[J].中外医学研究,2016,14(8):24-25. [4]董雪刚,郭丽春,刘祖松,等.阿立哌唑与舒必利治疗以阴性症状为主精神分裂症临床对照观察[J].中国健康心理学杂志,2015,23(4):501-504. [5]陈明旭.对氯氮平与阿立哌唑合用治疗以阴性症状为主的难治性精神分裂症的探讨[J].中国实用医药,2017,12(6):119-120. [6]杨叶,乔宇,王玉琴.阿立哌唑片和氯氮平治疗精神分裂症的临床疗效及不良反应[J].中国现代药物应用,2014,8(21):89-90. [7]郑喆.碳酸锂联合阿立哌唑口崩片治疗双相障碍抑郁发作的疗效和安全性[J].医药前沿,2016,6(24):235-236. [8]于晶,顾广中.草酸艾司西酞普兰联合阿立哌唑治疗伴有精神病性症状的重度抑郁发作的临床分析[J].中国现代药物应用,2016,10(23):102-103. [9]李真,李雪铮.帕罗西汀联合不同剂量阿立哌唑治疗强迫症临床疗效观察[J].现代医药卫生,2016,32(22):3448-3450. [10]郝红,赵宁民,朱雪萍,等.氟伏沙明联合阿立哌唑对强迫症患者临床症状及认知功能的影响[J].国际精神病学杂志,2017,44(2):243-246. [11]王秀芳,郭红丽,张宏伟.度洛西汀合并阿立哌唑治疗躯体形式障碍的临床对照研究[J].精神医学杂志,2013,26(3):209-210. [12]李侃,郭中孟,邹圣军.阿立哌唑对躯体形式障碍治疗的增效作用[J].张江大学学报(自然版),2013,10(33):14-16. [13]马文斌.阿立哌唑辅治酒精所致精神障碍临床观察[J].中国继续医学教育,2015,7(3):228-229. [14]李琪勇.阿立哌唑与帕利哌酮治疗酒精所致精神障碍对照研究[J].临床心身疾病杂志,2017,23(2):42-44. [15]刘渝斌.阿立哌唑与舒必利治疗甲基苯丙胺所致精神障碍的临床对照研究[J].心理医生,2017,23(15):31-33. [16]陈培栋,房利勤.阿立哌唑与利培酮治疗老年痴呆患者行为障碍及认知功能的影响研究[J].山西医药杂志,2017,46(3):334-336. [17]赵全军.阿立哌唑及利培酮对痴呆伴精神行为症状的疗效及安全性[J].中国实用神经疾病杂志,2016,19(7):111-112. [18]董勇,关靖宇.阿立哌唑和氟哌啶醇治疗脑外伤所致精神障碍疗效对比[J].中国继续医学教育,2015,7(15):161-162. [19]方琼,陈琅,陈巧彬.阿立哌唑治疗儿童抽动障碍疗效和安全性的Mate分析.[J].中国当代儿科杂志,2015(12):715-720. [20]吴传军,陈燕惠.经颅微电流刺激与阿立哌唑治疗儿童抽动障碍的对照研究[J].中国儿童保健杂志,2016,24(6):576-578. [21]张红,黄海忠,林国栋.利培酮与阿立哌唑治疗儿童抽动障碍的随机对照研究[J].临床荟萃,2015,30(12):1393-1396. [22]谭素仙.精神发育迟滞患儿临床表现及阿立哌唑治疗效果分析[J].中国药物与临床,2014,14(4):505-506. [23]谢琴,汤珺,徐杨,等.阿立哌唑治疗儿童孤独症的临床观察[J].中国当代儿科杂志,2013,15(4):294-297. [24]曹业才.阿立哌唑与利培酮治疗儿童青少年精神分裂症的临床对照观察[J].中国医药指南,2017,15(5):154-155. [25]刘敏,朱君.阿立哌唑治疗儿童精神病的临床疗效分析[J].世界临床医学,2017,11(1):166.

相似文献/References:

[1]邹超杰,程宇琪.肠道微生物在精神分裂症中的研究进展[J].医学信息,2018,31(02):29.[doi:10.3969/j.issn.1006-1959.2018.02.011]
　ZOU Chao-jie,CHENG Yu-qi.Progress in the Study of Intestinal Microorganism in Schizophrenia[J].Journal of Medical Information,2018,31(14):29.[doi:10.3969/j.issn.1006-1959.2018.02.011]
[2]张 健,江 芮.生活技能训练对精神分裂症缓解期患者日常生活能力的影响[J].医学信息,2018,31(03):118.[doi:10.3969/j.issn.1006-1959.2018.03.040]
　ZHANG Jian,JIANG Rui.Effect of Life Skills Training on Daily Living Ability of Patients with Schizophrenia in Remission Staged[J].Journal of Medical Information,2018,31(14):118.[doi:10.3969/j.issn.1006-1959.2018.03.040]
[3]沈雪梅.齐拉西酮与奥氮平治疗首发精神分裂症 疗效及糖脂代谢的影响观察[J].医学信息,2018,31(06):130.[doi:10.3969/j.issn.1006-1959.2018.06.044]
　SHEN XUE-mei.The Effect of Ziprasidone and Olanzapine in the Treatment of First Episode Schizophrenia and the Effect of Glycolipid Metabolism[J].Journal of Medical Information,2018,31(14):130.[doi:10.3969/j.issn.1006-1959.2018.06.044]
[4]陈功琦,梁道博.利培酮联合舍曲林治疗精神分裂症阴性症状 疗效和安全性的Meta分析[J].医学信息,2018,31(10):65.[doi:10.3969/j.issn.1006-1959.2018.10.020]
　CHEN Gong-qi,LIANG Dao-bo.Meta Analysis of Efficacy and Safety of Risperidone Combined with Sertraline in the Treatment of Schizophrenia with Negative Symptoms[J].Journal of Medical Information,2018,31(14):65.[doi:10.3969/j.issn.1006-1959.2018.10.020]
[5]廖鸿钊,钟建辉.氯氮平联合阿立哌唑、利培酮治疗难治性精神分裂症的疗效及对患者糖脂代谢水平的影响[J].医学信息,2022,35(09):141.[doi:10.3969/j.issn.1006-1959.2022.09.035]
　LIAO Hong-zhao,ZHONG Jian-hui.Clinical Efficacy of Clozapine Combined with Aripiprazole and Risperidone in the Treatment of Treatment Resistant Sehizophrenia and its Effect on Glucose and Lipid Metabolism[J].Journal of Medical Information,2022,35(14):141.[doi:10.3969/j.issn.1006-1959.2022.09.035]
[6]孙来顺.氨磺必利与利培酮对精神分裂症患者内分泌及糖脂代谢的影响[J].医学信息,2022,35(10):137.[doi:10.3969/j.issn.1006-1959.2022.10.033]
　SUN Lai-shun.Effects of Amisulpride and Risperidone on Endocrine And Glucose and Lipid Metabolism in Patients with Schizophrenia[J].Journal of Medical Information,2022,35(14):137.[doi:10.3969/j.issn.1006-1959.2022.10.033]
[7]孙占娟.精神分裂症患者的认知康复治疗进展[J].医学信息,2018,31(13):52.[doi:10.3969/j.issn.1006-1959.2018.13.015]
　SUN Zhan-juan.Progress in Cognitive Rehabilitation Therapy of Schizophrenia Patients[J].Journal of Medical Information,2018,31(14):52.[doi:10.3969/j.issn.1006-1959.2018.13.015]
[8]宋典雄.激励理论指导下的护理干预对精神分裂症患者的影响[J].医学信息,2018,31(18):166.[doi:10.3969/j.issn.1006-1959.2018.18.054]
　SONG Dian-xiong.The Effect of Nursing Intervention under the Guidance of Motivation Theory on Patients with Schizophrenia[J].Journal of Medical Information,2018,31(14):166.[doi:10.3969/j.issn.1006-1959.2018.18.054]
[9]凌 梅,刘静芳.精神分裂症患者研究伙伴的相关研究进展[J].医学信息,2018,31(19):48.[doi:10.3969/j.issn.1006-1959.2018.19.016]
　LING Mei,LIU Jing-fang.Progress in Research on Research Partners in Patients with Schizophrenia[J].Journal of Medical Information,2018,31(14):48.[doi:10.3969/j.issn.1006-1959.2018.19.016]
[10]韩佳睿,张 苹,张 媛.迟发性运动障碍与DNA甲基化之间关系的研究进展[J].医学信息,2018,31(20):32.[doi:10.3969/j.issn.1006-1959.2018.20.010]
　HAN Jia-rui,ZHANG Ping,ZHANG Yuan.Advances in Research on the Relationship between Tardive Dyskinesia and DNA Methylation[J].Journal of Medical Information,2018,31(14):32.[doi:10.3969/j.issn.1006-1959.2018.20.010]
[11]孙来顺.精神分裂症的药物治疗[J].医学信息,2021,34(21):42.[doi:10.3969/j.issn.1006-1959.2021.21.010]
　SUN Lai-shun.Drug Treatment of Schizophrenia[J].Journal of Medical Information,2021,34(14):42.[doi:10.3969/j.issn.1006-1959.2021.21.010]

更新日期/Last Update: 2018-07-15